Recommendations for the Use of Prolonged-Release Fampridine in Patients with Multiple Sclerosis (MS)

Warning

This publication doesn't include Faculty of Medicine. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.

Authors	PREININGEROVA Jana Lizrova BAUMHACKL Ulf CSEPANY Tunde CZAPLINSKI Adam DEISENHAMMER Florian DERFUSS Tobias FABJAN Tanja H. FAZEKAS Franz FUCHS Siegrid HAVRDOVA Eva LEDINEK Alenka Horvath ILLES Zsolt JAZBEC Sasa Sega KLIMOVA Eleonora KOMOLY Samuel KURCA Egon LINNEBANK Michael LISY Lubomir MARES Jan PROCHAZKOVA Lubica CSILLA Rozsa SZILASIOVA Jarmila ŠTOURAČ Pavel TALAB Radomir TURCANI Peter VACHOVA Marta VECSEI Laszlo VODUSEK David ZAPLETALOVA Olga BERGER Thomas
Year of publication	2013
Type	Article in Periodical
Magazine / Source	CNS NEUROSCIENCE &THERAPEUTICS
MU Faculty or unit	Central European Institute of Technology
Citation
Doi	http://dx.doi.org/10.1111/cns.12101
Field	Neurology, neurosurgery, neurosciences
Keywords	Aminopyridines; Fampridine; Multiple sclerosis; Walking
Description	Prolonged-release fampridine (fampridine PR) is a potassium channel blocker that improves conductivity of signal on demyelinated axons in central nervous system. Fampridine PR has been approved to improve speed of walking in patients with multiple sclerosis. This statement provides a brief summary of data on fampridine PR and recommendations on practical use of the medication in clinical practice, prediction, and evaluation of response to treatment and patient management.